Akers Biosciences on the road to commercialisation - 500 Beiträge pro Seite

[Jon_Schnee]

Capitalization Structure

Common Stock -> 4,894,837
Warrants – Average Exercise Price of $71.76 -> 1,989

Total Fully Diluted -> 4,896,826

[Jon_Schnee]

[Jon_Schnee]

Homepage: http://www.akersbiosciences.com/

Events & Presentations: http://ir.akersbiosciences.com/events.cfm


ProActiveInvstor UK: http://www.proactiveinvestors.co.uk/LON:AKR/Akers-Bioscience…

Yahoo Finance USA: https://finance.yahoo.com/q?s=AKER

[Jon_Schnee]

Overview

•ABI develops, manufactures and supplies rapid diagnostic tests for hospital laboratories, government, military, law enforcement, on-the-job safety, doctors’ offices and home use

•Four of ABI’s six proprietary platform technologies have lead to the development of 11 core products, each with mass market potential

•Sales and distribution though blue chip medical products companies

•Core Strategy: Identify high margin market segments with inadequate testing solutions and introduce ABI’s rapid alternative

•Underpinned by valuable proprietary platform technology base

•10 Utility & 6 Design patents granted in force; 10 Utility patent applications pending

•Manufacturing facility approved by FDA (GMP), LNE (French NF X20-720 Standard), SAI Global (Australian AS 3547-1997 Standard)

•Registered US Government Contractor (GSA contract GS-07F-0140W)

•2013 revenues increased by 129% to $3.6 million (2012: $1.6 million)


http://files.shareholder.com/downloads/AMDA-2AXZNZ/328009151… Seite 4

[Jon_Schnee]

Pipeline / Products:




http://files.shareholder.com/downloads/AMDA-2AXZNZ/328009151… Seite 8

[Jon_Schnee]

Plattform Technologie siehe Seite 7:
http://files.shareholder.com/downloads/AMDA-2AXZNZ/328009151…


Global Target Market Statistics by Technology Platform



http://files.shareholder.com/downloads/AMDA-2AXZNZ/328009151… Seite 6

[Jon_Schnee]

NEWS

Akers Biosciences Signs Agreement With Medline -- a Major US Distributor
https://finance.yahoo.com/news/akers-biosciences-signs-agree…

Akers Biosciences Signs US Distribution Agreement With Typenex
https://finance.yahoo.com/news/akers-biosciences-signs-us-di…


"Following the signing of the Agreement, our tests for HIT-antibodies are now being marketed by the three largest distributors of healthcare supplies in the United States. This Agreement, in conjunction with Typenex's highly targeted approach, gives the Company the broadest marketing coverage across the United States for these products since launch. We are delighted to be partnering with Medline which enjoys strong relationships with its customers and benefits from a vast distribution network," said Dr. Akers.

[Jon_Schnee]

Antwort auf Beitrag Nr.: 47.209.752 von Jon_Schnee am 25.06.14 20:18:32

Nicht nur USA, sondern auch Indien:

Akers Biosciences Signs Agreement to Market Rapid Tests in India
https://finance.yahoo.com/news/akers-biosciences-signs-agree…

[Jon_Schnee]

Akers Biosciences tests positive for growth potential
http://www.proactiveinvestors.co.uk/companies/news/69804/ake…

[Jon_Schnee]

Akers partner will distribute breakthrough allergy test to US hospitals
By Ian Lyall

http://www.proactiveinvestors.co.uk/companies/news/69786/ake…

Shares in Akers Biosciences (LON:AKR, NSADAQ:AKER) rose sharply after it took a significant step closer to commercialising one of its potential blockbuster products.

It signed an agreement with Medline, which will distribute its point of care tests used to determine a patient’s allergy to the blood thinner Herparin.

Called PF4 and PIFA PLUSS PF4, the devices work by detecting tell-tale HIT-antibodies associated with an allergic reaction.

In the States around 12mln patients are exposed to Heparin annually, and 1%-5% of those are diagnosed with HIT.

Medline is expected to start marketing the tests to its large network of hospitals and surgery centres across the US immediately.

"Our goal is to become the hospital's test of choice for the millions of patients exposed to Heparin annually," said chairman Ray Akers.

He added that HIT-antibody testing has in the past been too slow to be factored into time-sensitive diagnostic and treatment decisions.

However, the Akers boss added: "We believe that our rapid assays, which can be completed at the point-of-care, have the capacity to drastically improve the rate at which HIT-antibodies are identified, improve patient outcomes and save large sums of money for hospitals prescribing expensive alternatives to Heparin unnecessarily while awaiting results from slow lab-based tests.”

Not only does this speed up the process, but it rapidly reduces the cost too.

The shares rose 45p to 315p following the news. However, City broker Daniel Stewart, which restarted coverage of Akers this morning, reckons the stock is worth 752p a share, which points to significant potential upside.

Analyst Vadim Alexandre cites the group’s January listing on the American NASDAQ tech exchange as a significant breakthrough for the business.

“With an additional $15mln of cash (gross) from the IPO, and supported by a reinvigorated marketing strategy, ABI is poised to accelerate the roll-out of its diagnostics product portfolio and pipeline,” was one of the major headlines from the 28-page note.

[Jon_Schnee]

langsam wird der Kurs intressant zum Einstieg. 3.19 USD ist an der Nasdaq derzeit das tief (derzeit 3.45 USD). Wenn man Gesamtmarkt sieht drängt sich panik Kauf nicht auf. Warte noch einwenig.

[Jon_Schnee]

hier geht es richtig zur Sache. Kurs wieder unter 3 USD. So langsam juckt mich es zu kaufen, der Downtrend ist mir aber noch zu stark.

[Jon_Schnee]

Akers Biosciences Announces $864,000 Sales Contract for Its Rapid Results Point of Care Cholesterol Test

New Cholesterol Test Takes Only Three Minutes to Produce Results; Addresses a Worldwide Market Estimated at $2 Billion

THOROFARE, N.J., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (AKER) (AIM:AKR.L), (the "Company" or "ABI"), a leading designer and manufacturer of rapid diagnostic screening and testing products, announced a contract valued at $864,000 for sales of its innovative Tri-Cholesterol "Check" tests in Australia, Singapore, the United Arab Emirates and Oman. The Company's products are being distributed in such regions by 36 Strategies General Trading LLC ("36S"), a Dubai-based procurement solutions company. Target customers in Australia, Singapore, the United Arab Emirates and Oman include military forces, medical associations, universities and large companies operating in the resources sector.

The Company's Tri-Cholesterol "Check" is a revolutionary finger-stick blood sample technology and the only combined rapid test which provides an estimate of both Total and High Density Lipoprotein ("HDL") cholesterol levels; thereby providing an estimate of the subject's Low Density Lipoprotein ("LDL") levels.

ABI's Tri-Cholesterol "Check" test carries a U.S. Food and Drug Administration ("FDA") Over-the-Counter approval; three CE marks for the European Economic Area; and a Health Canada approval.

Raymond F. Akers Jr., Ph.D, Executive Chairman of Akers Biosciences, stated, "This order gives us confidence that this test could become a very important and widely used test worldwide. There are an estimated 200 million people worldwide who have abnormal cholesterol levels. Our self-administered point-of-care test for cholesterol is easy-to-use, low cost, and revolutionary in point-of-care diagnostics. We are very pleased with the sales results we have achieved in these regions in a very short time through our distribution partner in the Middle East."

Revenue related to this order for Tri-Cholesterol "Check" tests (a Rapid Enzymatic Assay product) was recognized in the accounts for the six months ended June 30, 2014.


ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.



https://finance.yahoo.com/news/akers-biosciences-announces-8…

[Jon_Schnee]

Antwort auf Beitrag Nr.: 47.739.225 von Jon_Schnee am 10.09.14 06:31:52

The contract win comes less than five months after the company’s tie-up with distributor Thirty Six Strategies General Trading (36S), which gives 36S exclusive rights to market the company’s products in Australia, Singapore, the United Arab Emirates and Oman, for a three-year period.

“We are very pleased with the sales results we have achieved in these regions in a very short time through our distribution partner in the Middle East," Akers said.


http://www.proactiveinvestors.co.uk/companies/news/72042/ake…

[Jon_Schnee]

UPDATE - Akers Biosicences sets up China joint venture to fill hole in coverage

By Philip Whiterow
October 24 2014
http://www.proactiveinvestors.co.uk/companies/news/73588/upd…

Medical diagnostics specialist Akers Biosciences (LON:AKR) has set up a joint venture to research and market its products in China.

Hainan Savy Investment Management and Akers’ chairman Thomas Knox are the two other partners in the venture, which will be based in Haikou, in Hainan province. The joint venture will be known as Hainan Savy Akers Biosciences.

Akers said the joint venture will eventually establish a manufacturing operation in the same area.

China is among the world’s fastest growing in vitro diagnostics markets with an annual growth rate estimated at 18%.

Most of Akers’ current products will be marketed by the new company, though the emphasis will be Akers' diabetes, cardiac, and infectious diseases rapid diagnostic screening and testing products.

Akers is currently best know for its Breath Ketone test for diabetic monitoring, CHUBE disposable breath alcohol detectors, Tri-Cholesterol test, and PIFA (based tests for infectious diseases.

Raymond Akers Jr, Aker’s executive chairman, described the new venture as a landmark for the company and follows recent distribution agreements in the US, Middle East, and Asia.

“This will also enable us to design and manufacture new rapid diagnostic screening and testing products in China," he said.

"The creation of this joint venture is a timely move designed to meet the growing demand in the rapidly expanding Chinese market.

"We look forward to working closely with Hainan going forward."

Broker FinnCap noted that China’s IVD (in vitro diagnostic) market was estimated to be worth US$2.1bn in 2012, with a growth rate of about 25% a year.

Quoting one source, it said the number of clinical laboratories in China was estimated to be around 20,000, which corresponds to the number of hospitals in the country.

Yesterday, shares jumped 8% to 250p but on Friday were unchanged at 240p.

[Jon_Schnee]